Gut microbiota biomarkers could help diagnose schizophrenia: Research

By Cheryl Tay

- Last updated on GMT

Sequencing technology has created an avenue to characterise schizophrenia through underlying probing of the gut microbiome. ©Getty Images
Sequencing technology has created an avenue to characterise schizophrenia through underlying probing of the gut microbiome. ©Getty Images

Related tags Gut microbiota

Gut microbiota could influence and help diagnose schizophrenia, according to researchers in China.

Sequencing technology has created an avenue to characterise schizophrenia through underlying probing of the gut microbiome, which could in turn provide clues to aid in the diagnosis and prognosis of schizophrenia.

Researchers at Peking University and the Chinese Academy of Sciences and compared the differences in gut microbiota between healthy controls and those who had been diagnosed with schizophrenia, using 16S rRNA sequencing.

They then investigated whether gut microbiota could serve as a biomarker to help in the diagnosis of schizophrenia, making sure to restrict "inclusion criteria strictly to control confounding bias"​.

As a last step, they looked into differences in faecal microbiota between 64 schizophrenia patients and 53 healthy controls.

Microbiota biomarkers

The researchers noted that at the phylum level, the abundance of Proteobacteria​ in the schizophrenia patents was "significantly increased"​.

At the genus level, Succinivibrio, Megasphaera​, Collinsella​, Clostridium​, Klebsiella ​and Methanobrevibacter ​were higher in relative abundance, while Blautia​, Coprococcus ​and Roseburia​ were more prominent in the healthy controls.

They observed that 12 significant microbiota biomarkers could be used as diagnostic factors for determining if someone was schizophrenic or not.

They added that "several metabolic pathways differed significantly between healthy controls and schizophrenia patients, including vitamin B6 and fatty acids"​.

Factors to consider

However, the researchers also acknowledged the limitations of the study, one of which was its cross-sectional design that included only schizophrenic individuals of Chinese Han nationality. As such, they deemed the sample size too small.

At the same time, they did not manage to full eliminate the impact anti-psychotic drugs had on the gut microbiota.

As such, they wrote that the sample size should be bigger and that they should select "multi-ethnic patients" ​whose first episode of schizophrenia had not been treated, and involve them in "longitudinal follow-up studies to observe the dynamic changes of gut microbiota"​.

Despite this, they added that comparing the differences in gut microbiota between healthy individuals and those with schizophrena presented a new aspect of gut microbiota’s health potential.

They concluded: "There are some differences of gut microbiota between schizophrenia patients and healthy controls, and the insights from this study could be used to develop microbiota-based diagnosis for schizophrenia."

 

Source: Schizophrenia Research

https://doi.org/10.1016/j.schres.2018.01.002

"Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study"

Authors: Yang Shen, et al.

Related news

Related products

show more

Krill oil supports six key areas of healthy aging

Krill oil supports six key areas of healthy aging

Content provided by Aker BioMarine | 26-Feb-2024 | White Paper

The global population is getting older—according to WHO by 2050 the world’s population over 60 years will double and the population above 80 years will...

Nootropics Report 2.0: Brain Health Insights

Nootropics Report 2.0: Brain Health Insights

Content provided by dsm-firmenich | 22-Feb-2024 | Insight Guide

The brain health market is constantly growing and evolving, with more consumers looking for innovative ways to support total mind and body wellness.

Revolutionizing Brain Health with BioKesum®

Revolutionizing Brain Health with BioKesum®

Content provided by Biotropics Malaysia | 20-Feb-2024 | Data Sheet

Revitalize the nootropic industry with new clinically proven herbal extract from Kesum leaves shown to improve executive memory, mood and brain markers...

Pycnogenol® Supports Cognitive Function at Any Age

Pycnogenol® Supports Cognitive Function at Any Age

Content provided by Horphag Research | 07-Feb-2024 | White Paper

Clinical research shows daily supplementation with Pycnogenol® French maritime pine bark extract may help support brain function in a variety of age groups...

Related suppliers

Follow us

Products

View more

Webinars

Nutra Champions Podcast

Nutra Champions Podcast